Skip to Content
  • Previous Rank
    263
  • Revenues ($M)
    $11,449
  • Revenue Percent Change
    6.4%
  • Profits ($M)
    $3,702.8
  • Profits Percent Change
    4.4%
  • Assets ($M)
    $22,877
  • Employees
    7,400
  • Market Value — as of March 31, 2017 ($M)
    $59,046

The biotechnology company discovers and manufactures treatments for autoimmune disorders, neurodegenerative diseases and hemophilia.

Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Info

CEO
Michel Vounatsos
CEO Title
Chief Executive Officer & Director
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Cambridge, MA
Websitehttp://www.biogen.com
Years on Fortune 500 List8
Employees7,400

Biogen Rank History

placeholder

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$11,4496.4%
Profits ($M)$3,702.84.4%
Assets ($M)$22,877-
Total Stockholder Equity ($M)$12,140-
Market Value — as of March 31, 2017 ($M)$59,046-

Profit Ratios

Profit as % of Revenues32.3%
Profits as % of Assets16.2%
Profits as % of Stockholder Equity30.5%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)16.93
EPS % Change (from 2015)10.4%
EPS % Change (5 year annual rate)27.4%
EPS % Change (10 year annual rate)39%

Total Return

Total Return to Investors (2016)-7.4%
Total Return to Investors (5 year, annualized)20.8%
Total Return to Investors (10 year, annualized)19.1%